Verition Fund Management
TGTX icon

Verition Fund Management’s TG Therapeutics TGTX Stock Holding History

Verition Fund Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-46,896
Closed -$1.69M – 3943
2025
Q3 		$1.69M Buy
46,896
+19,265
+70% +$635K 0.01% 2113
2025
Q2 		$994K Sell
27,631
-2,514
-8% -$93.6K ﹤0.01% 2480
2025
Q1 		$1.19M Buy
30,145
+10,680
+55% +$359K 0.01% 1990
2024
Q4 		$586K Sell
19,465
-26,234
-57% -$753K ﹤0.01% 2383
2024
Q3 		$1.07M Sell
45,699
-6,613
-13% -$144K 0.01% 1842
2024
Q2 		$931K Buy
52,312
+35,655
+214% +$569K 0.01% 1718
2024
Q1 		$253K Buy
16,657
+2,553
+18% +$40.7K ﹤0.01% 2385
2023
Q4 		$241K Sell
14,104
-39,003
-73% -$453K ﹤0.01% 1915
2023
Q3 		$444K Buy
53,107
+38,292
+258% +$534K 0.01% 1511
2023
Q2 		$368K Sell
14,815
-10,180
-41% -$263K ﹤0.01% 1407
2023
Q1 		$376K Buy
+24,995
New +$380K 0.01% 1391

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Verition Fund Management's TGTX Position: Q4 2025 in Review

Verition Fund Management sold out of TG Therapeutics (TGTX) in Q4 2025, closing a stake of 46,896 shares — an estimated $1.69M sold.

Verition Fund Management first reported a position in TGTX in Q1 2023 and held it in 11 quarters. The position peaked at $1.69M in Q3 2025. 351 funds tracked by Wall St. Rank hold TGTX as of Q4 2025.

  • Verition Fund Management reported no remaining TG Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Verition Fund Management sold 46,896 TG Therapeutics shares in Q4 2025, an estimated $1.69M.
  • Verition Fund Management first reported a position in TG Therapeutics in Q1 2023 and held it in 11 quarters.
  • Verition Fund Management's TG Therapeutics position peaked at $1.69M in Q3 2025.
  • 351 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2025.

Based on Verition Fund Management's 13F filing for Q4 2025, filed 13 Feb 2026.